Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status approved
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII 99DK7FVK1H
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.0070.003978%Not Available
Tendon disorder12.01.07.019; 15.07.01.0020.010608%Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.0080.005304%
Ulcer08.03.06.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.0080.002652%
Vertical infection transmission18.03.03.010; 11.07.02.005--Not Available
Vomiting07.01.07.0030.009813%
Fat redistribution14.08.04.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.0080.002652%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Conjunctival hyperaemia06.04.01.0040.003978%Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus07.01.06.026; 09.01.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Cerebral disorder17.02.10.0170.002652%Not Available
Body fat disorder14.08.04.012--Not Available
Dyslipidaemia14.08.04.0150.002652%Not Available
Drug resistance08.06.01.0050.006630%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Adverse event08.06.01.0100.003978%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Inflammation08.01.05.007; 10.02.01.089--Not Available
Malnutrition14.03.02.0040.002652%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene